Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.57 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | CPA1 | P15085 | 3/20 | 0.52 |
| ▸ | CPA2 | P48052 | 3/20 | 0.52 |
| ▸ | CPA4 | Q9UI42 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468907 | 1.00 | GNPAT (0.57) | GNPATMMEACECPA1CPA2 | |
| SCHEMBL6931278 | 1.00 | GNPAT (0.57) | GNPATMMEACECPA1CPA2 | |
| SCHEMBL14400980 | 0.90 | GNPAT (0.61) | GNPATCPA1CPA2CPA4CTSS | |
| SCHEMBL5505937 | 0.90 | GNPAT (0.61) | GNPATCPA1CPA2CPA4CTSS | |
| SCHEMBL7428179 | 0.87 | MEN1 (0.49) | CPA1CPA2CPA4MEN1HTT | |
| SCHEMBL11555675 | 0.87 | MEN1 (0.49) | CPA1CPA2CPA4MEN1HTT | |
| SCHEMBL7432316 | 0.87 | MEN1 (0.49) | CPA1CPA2CPA4MEN1HTT | |
| SCHEMBL2558591 | 0.87 | ALB (0.49) | GNPATCPA1CPA2CPA4MEN1 | |
| SCHEMBL14350869 | 0.86 | MME (0.58) | MMEACECPA1MEN1HTT | |
| SCHEMBL29443417 | 0.85 | GNPAT (0.57) | GNPATMMEACECPA1CPA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3039068-B1 | MOISTURE CURABLE COMPOUND WITH AMINO ACIDS | MOMENTIVE PERFORMANCE MAT INC (US) | 2020-12-16 | — | — | EP | claimed |
| US-9914809-B2 | Moisture curable composition with amino acids | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2018-03-13 | — | — | US | claimed |
| US-20160200880-A1 | MOISTURE CURABLE COMPOSITION WITH AMINO ACIDS | MOMENTIVE PERFORMANCE MATERIALS INC. | 2016-07-14 | — | — | US | claimed |
| EP-3039068-A1 | MOISTURE CURABLE COMPOUND WITH AMINO ACIDS | Momentive Performance Materials Inc. (US) | 2016-07-06 | — | — | EP | claimed |
| WO-2015031712-A1 | MOISTURE CURABLE COMPOUND WITH AMINO ACIDS | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2015-03-05 | — | — | WO | claimed |
| US-RE44302-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-06-18 | — | — | US | claimed |
| US-RE44017-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-02-19 | — | — | US | claimed |
| US-RE42902-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2011-11-08 | — | — | US | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-RE41278-E1 | N-acetyl aldosamines and related N-acetyl compounds, and their topical use | TRISTRATA, INC. | 2010-04-27 | — | — | US | claimed |
| EP-2080504-A2 | Topical composition comprising n-acetylaldosamines or n-acetylamino acids | Yu, Ruey J. (US) | 2009-07-22 | — | — | EP | claimed |
| EP-1639994-A2 | Topical composition comprising N-acetylaldosamines or N-acetylamino acids | Yu, Ruey J., Dr. (US) | 2006-03-29 | — | — | EP | claimed |
| EP-1570840-A2 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2005-09-07 | — | — | EP | claimed |
| US-6524593-B1 | Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails | TRISTRATA, INC. | 2003-02-25 | — | — | US | claimed |
| EP-1143925-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2001-10-17 | — | — | EP | claimed |
| US-6159485-A | COSMETICS; SKIN DISORDERS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-12-12 | — | — | US | claimed |
| WO-2000040217-B1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-10-05 | — | — | WO | claimed |
| WO-2000040217-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-07-13 | — | — | WO | claimed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| EP-0338330-B1 | PROCESS FOR PREPARING N-ACYL-AMINO ACIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | GNPAT 1000/4885MME 1765/4885ACE 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.